HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hain filing delay

This article was originally published in The Rose Sheet

Executive Summary

Hain Celestials has requested a hearing before a NASDAQ Listing Qualifications Panel to request continued listing on the stock market, the firm announces Sept. 20. On Sept. 14, the natural-food and personal-care company received a staff determination letter indicating that Hain is not in compliance with NASDAQ filing requirements due to a delay in filing Form 10-K. Hain shares will continue to be listed on NASDAQ pending a decision by the Listing Qualifications Panel. Hain says it is conducting a review of its stock-option practices under the direction of "a group of independent investors" and independent legal counsel. "The timing of that completion has resulted in a delay in finalizing the company's annual report on form 10-K," Hain says. Company notes that the results of the review and any changes recommended by reviewers will not affect its Q4 and FY 2007 results...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014981

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel